Roche Acquires Microbial Dx Firm GeneWeave for up to $425M | GenomeWeb

NEW YORK(GenomeWeb) – Roche today announced it has signed a definitive agreement to acquire clinical diagnostics firm GeneWeave BioSciences for as much as $425 million.

Under the terms of the agreement, Roche will make a $190 million upfront payment to GeneWeave's shareholders and could pay an additional $235 million in product-related milestones. Once the deal is closed, Roche will integrate GeneWeave into its Molecular Diagnostics unit.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.